Results 151 to 160 of about 104,102 (262)

Adverse reactions to intravenous immunoglobulin in primary immunodeficiency: a retrospective analysis. [PDF]

Postepy Dermatol Alergol
Demirel F, Kalkan F, Selcuk A, Yesillik S, Kartal O.   +4 more
europepmc   +1 more source

Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia

BMEMat, EarlyView.
CPDS combines drugs with three different mechanisms of action to achieve a multi‐mechanism combination therapy for AML by directly killing tumor cells and activating anti‐tumor immunity. Abstract As the main acute myeloid leukemia (AML) clinical treatment, the chemotherapy alone cannot meet the clinical therapeutic needs due to the high heterogeneity ...
Meihong Chai, Rui Zhang, Haiyin Yang, Jiyue Xing, Tianyuan Hu, Mengxi Zhu, Rui Li, Xiaoli Chen, Beibei Zhao, Yang Lan, Stefan Barth, Yuanyu Huang, Li Zhang, Mengjie Zhang, Huining He   +14 more
wiley   +1 more source

Pharmacokinetic Model Based Sensitivity Analysis to Lower Recruitment Burden for Young Children Requiring Intravenous Immunoglobulin G Replacement. [PDF]

CPT Pharmacometrics Syst Pharmacol
Dumas T, Mehr S, Avila R, Doman A, Kestenberg K, Melamed I.   +5 more
europepmc   +1 more source

Real time in vivo efficacy monitoring of desialylation and perforation enhanced immunotherapy of cancer

BMEMat, EarlyView.
A multifunctional nanomedicine is designed to engineer NK cells for enhanced cancer immunotherapy through perforation and desialylation, enabling real‐time monitoring of ATP and GrB levels for precise efficacy assessment. Abstract Efficient enhanced NK cell therapy is of critical importance in the immune treatment of cancer.
Yuanjiao Yang, Yuru Wang, Xuemei Li, Chaoyi Yang, Yuhui Yang, Yanyun Fang, Lin Ding, Yunlong Chen, Huangxian Ju   +8 more
wiley   +1 more source

Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain-Barré syndrome. [PDF]

Orphanet J Rare Dis
Zhang H, Zhai F, Su M, Zhang Y, Ma J, Zhao J, Wang J, Chang X, Liu Y, Guo J, Zhang W.   +10 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Evaluating the association between intravenous immunoglobulin and thromboembolic events in patients with autoimmune diseases: a retrospective real-world study. [PDF]

Front Pharmacol
Chen J, Hu J, Zhang Y, Wang S, Yang W, Yang M, Ye Z, Dai H.   +7 more
europepmc   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report. [PDF]

Clin Case Rep
Sahebari M, Karimoddini M, Tayyebi Meibodi N, Ataei Azimi S, Tafreshian S.   +4 more
europepmc   +1 more source

Circulating monocyte partitioning and its alteration in hematological chronic neoplasms

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Circulating monocyte partitioning refers to the relative quantification of the three main monocyte subsets in the peripheral blood, namely classical (cMo), intermediate (iMo), and non‐classical (ncMo) monocytes, as assessed by flow cytometry, a new nomenclature described 15 years ago.
Sihem Tarfi, Dorothée Selimoglu‐Buet, Ivan Sloma, Orianne Wagner‐Ballon, on behalf of the French group CytHem‐LMMC   +4 more
wiley   +1 more source